Ningbo Coelac Minohua Pharmaceutical

Ningbo Coelac Minohua Pharmaceutical is a joint venture between the Chinese pharmaceutical group Ningbo Menovo Pharmaceutical and the Japanese company Coelacanth Corporation. The company specializes in the research, development, and manufacturing of high-quality active pharmaceutical ingredients (APIs) and advanced intermediates, primarily focusing on small molecule therapeutics. Its product portfolio is heavily weighted toward cardiovascular health, including treatments for hypertension, hyperlipidemia, and anticoagulation. Coelac Minohua operates as a key manufacturing and R&D hub within the Menovo Group, leveraging international quality standards to serve both domestic and global markets.